PT-141 Nasal Spray Dosage Chart: What Reported Ranges Actually Look Like

There is no official PT-141 nasal spray dosage chart. Bremelanotide, the drug commonly called PT-141, is FDA-approved only as a 1.75 mg subcutaneous injection (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, and no nasal version has been approved for human use in the United States. The intranasal numbers circulating online come from discontinued early research and from user reports, and they range from well under 1 mg to 20 mg.

Is There an Official PT-141 Nasal Spray Dosage Chart?

No. Bremelanotide began clinical development as a nasal spray, but the nasal program was shelved because absorption through the nasal lining was inconsistent and blood pressure rose more than expected. The developer later moved to the subcutaneous injection that won FDA approval in 2019.

Bremelanotide is not FDA-approved as a nasal spray for any indication, which means there is no label, no validated dosing table, and no standard concentration per spray. Older nasal trials used doses in the 10 mg to 20 mg range, far above the 1.75 mg injected dose, because so little of the drug crossed the nasal mucosa.

Because no regulated nasal product exists, two bottles labeled with the same strength can deliver very different amounts per squeeze. That single fact is why a dependable PT-141 nasal spray dosage chart does not exist.

PT-141 Nasal Spray Dosage Chart: Commonly Reported Ranges

The table below collects numbers that appear in community discussions and in older published research. It summarizes what people report, not what anyone should take.

If you search pt-141 nasal spray dosage reddit threads, the same pattern shows up: reported doses scatter across a wide range, and almost nobody states the concentration of their bottle. Reported pt-141 nasal spray dosage for men is generally the same as what women report, because the drug acts on melanocortin receptors rather than sex-specific pathways.

Nasal Spray vs Injection: Key Differences

The pt-141 nasal spray vs injection comparison comes down to predictability more than raw potency.

Nasal delivery avoids needles, but it trades convenience for control. Nausea, flushing, and headache are reported with both routes, and nasal irritation, congestion, or a runny nose can change how much drug is absorbed from one use to the next.

How People Time and Space Intranasal Doses

Timing often matters more than the exact number, because the effect window is short.

• Dose roughly 30 to 60 minutes before anticipated activity.
• Do not repeat within 24 hours; the FDA label for the injection caps total use at 8 doses per month.
• Avoid stacking PT-141 with other drugs that raise blood pressure, or with heavy alcohol use, without medical guidance.
• Some users eat beforehand to blunt nausea, though that is an anecdotal workaround rather than a studied strategy.
• Log every dose, the concentration of the bottle, and how you felt, since your own record is the only reliable chart you will have.

Side Effects and Safety Considerations

Bremelanotide temporarily raises blood pressure and slightly lowers heart rate. Common side effects include nausea, flushing, headache, and vomiting, and focal hyperpigmentation of the skin and gums has been reported with repeated use.

Bremelanotide is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease, and it should not be combined with other blood-pressure-raising medications without a clinician's review.

Nasal use adds risks that have nothing to do with the molecule itself: unverified purity, non-sterile solutions, and inconsistent dosing. A pt-141 peptide nasal spray sold for research purposes is not manufactured under pharmacy standards and is not intended for human use.

Anyone considering this route should speak with a healthcare professional first, especially if they take blood pressure medication or have a heart condition.

Why Homemade and Research-Grade Sprays Are Unpredictable

Guides on how to make pt-141 nasal spray usually describe dissolving lyophilized powder in bacteriostatic water or saline and transferring it into a metered spray bottle. The arithmetic looks simple on paper, but home compounding rarely produces accurate, sterile, or repeatable doses.

Common failure points include:

• Peptide powder that is underdosed or degraded during shipping.
• Spray bottles that deliver anywhere from 0.05 mL to 0.15 mL per actuation, which can triple or halve the intended dose.
• No sterility testing, preservative verification, or pH control.
• Inconsistent technique, such as sniffing hard, aiming at the septum, or spraying into a congested nose.

Nasal bremelanotide is not commercially available in the United States, and compounding rules restrict copies of approved drugs, so legitimate prescription access is limited. Even a properly prepared compounded spray remains unapproved and off-label.

What This Means Practically

Without a validated chart, the only defensible approach is conservative: verify the exact concentration per spray, start well below any figure you see quoted, and get medical clearance first. Anyone who needs a consistent, reproducible dose is better served by the FDA-approved injection than by an unapproved nasal product.